| Diabetes Mellitus
Semglee vs Novolog
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Semglee vs Insulin Diluting Medium For Novolog with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsInsulin Diluting Medium For Novolog has a higher rate of injection site reactions vs Semglee based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Insulin Diluting Medium For Novolog but not Semglee, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Semglee
Insulin Diluting Medium For Novolog
At A Glance
SC injection
Once daily
Long-acting insulin analog
SC injection
Pre-meal
Rapid-acting insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus, Type 1 Approximately one-third of total daily insulin requirements SC once daily at the same time each day; use concomitantly with short-acting premeal insulin.
Diabetes Mellitus, Type 2 0.2 units/kg or up to 10 units SC once daily at the same time each day for insulin-naive patients; individualize based on metabolic needs and glycemic goals.
Diabetes Mellitus Inject SC within 5-10 minutes before a meal into the abdominal area, thigh, buttocks, or upper arm; generally used with an intermediate- or long-acting insulin; may also be administered via continuous SC infusion pump or diluted to 0.05-1 unit/mL for IV infusion; individualize dose based on metabolic needs and blood glucose monitoring results.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin glargine products or any excipient in Semglee
- Episodes of hypoglycemia
- Hypersensitivity to NOVOLOG or one of its excipients
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, infection, accidental injury, headache
Serious Severe hypoglycemia, anaphylaxis and generalized hypersensitivity reactions, hypokalemia, peripheral edema, lipodystrophy
Postmarketing Medication errors with rapid-acting insulins administered instead of insulin glargine, localized cutaneous amyloidosis at injection site
Most common (>=5%) Headache, accidental injury, nausea, diarrhea (type 1 diabetes); hyporeflexia, onychomycosis, sensory disturbance, urinary tract infection, chest pain, skin disorder, abdominal pain, sinusitis (type 2 diabetes)
Serious Severe hypoglycemia, generalized allergy/anaphylaxis, hypokalemia, lipodystrophy, peripheral edema
Postmarketing Localized cutaneous amyloidosis at injection site, medication errors with insulin substitution, hyperglycemia or hypoglycemia associated with amyloidosis-related injection site changes
Pharmacology
Insulin glargine-yfgn is a long-acting human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production; it also inhibits lipolysis and proteolysis and enhances protein synthesis.
Rapid-acting human insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, with peak glucose-lowering effect 1-3 hours after SC injection and duration of action 3-5 hours.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Semglee
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (3/12) · Qty limit (6/12)
Insulin Diluting Medium For Novolog
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Semglee
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Insulin Diluting Medium For Novolog
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Semglee
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Insulin Diluting Medium For Novolog
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Semglee.
No savings programs available for Insulin Diluting Medium For Novolog.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SemgleeView full Semglee profile
Insulin Diluting Medium For NovologView full Insulin Diluting Medium For Novolog profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.